Five prominent RTKs, namely HER2 [178, 179], EGFR [180, 181], c-mesenchymal-epithelial transition factor (c-MET) [182, 183], ROR1 [177] and AXL [184], have demonstrated satisfactory outcomes as targets for CAR-T cell therapy in preclinical models of breast cancer. This evidence concerns the gene ERBB2 and breast cancer.